Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Praxis Precision Medicines, Inc. (PRAX)

Praxis reports Q2 2026 net loss of $83.7 million, up from $71.1 million a year earlier

Mixed Impact 3 of 5 earnings Written later

Praxis Precision Medicines reported a second-quarter 2026 net loss of $83.7 million, up from $71.1 million in the same quarter of 2025, as research and development and general and administrative expenses both rose. The company said the FDA completed mid-cycle meetings and BIMO inspections for its two pending applications, and that cash and investments of $1.4 billion fund operations into 2028.

Key points

  • Net loss of $83.7 million for Q2 2026 versus $71.1 million for Q2 2025; loss per share was $2.87 versus $3.31
  • General and administrative expenses rose to $27.5 million from $13.1 million, mainly due to $7.2 million in higher professional expenses
  • Relutrigine PDUFA target action date set at December 27, 2026; ulixacaltamide PDUFA date is January 29, 2027
  • Cash, cash equivalents and marketable securities of $1.4 billion as of June 30, 2026

The filing

CompanyPraxis Precision Medicines, Inc. (PRAX)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:31 AM ET
Accession number0001689548-26-000082

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.